Fair Value Measurements and Investments - Additional Information (Detail) SFr in Millions			1 Months Ended		12 Months Ended
	Oct. 01, 2020 USD ($)	Apr. 30, 2018 USD ($)	Nov. 30, 2021 USD ($)	Oct. 01, 2019 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 10, 2021 USD ($)	Oct. 10, 2021 CHF (SFr)	Oct. 01, 2020 CHF (SFr)
Spinal Kinetics [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Milestone achievement period		5 years			12 months
Contingent consideration					$ 17,200,000
Payment for contingent consideration liability					30,000,000.0
Spinal Kinetics [Member] | Other Current Liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration					17,200,000
Maximum [Member] | Spinal Kinetics [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Future milestone payments		$ 60,000,000.0
US Food And Drug Administration [Member] | Spinal Kinetics [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Future milestone payments		15,000,000.0
Revenue Milestone [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Future milestone payments					15,000,000.0
Revenue Milestone [Member] | Spinal Kinetics [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Future milestone payments		$ 45,000,000.0
eNeura Inc [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Payments of debt security				$ 4,000,000.0
Other-than-temporary impairment on debt securities				6,500,000
eNeura Inc [Member] | Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Unrealized gains on debt securities				$ 5,200,000
Equity Warrants | Bone Biologics Inc [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Impairment charges on investment						$ 200,000
Neo Medical [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible loans							$ 700,000	SFr 0.6	SFr 4.6
Convertible loans interest rate									8.00%
Maturity date	Oct. 01, 2024
Convertible loan credit losses					0
Neo Medical [Member] | Other Income [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Unrealized gain (loss) on equity investments			$ 400,000
Preferred Stock [Member] | Neo Medical [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amount of Preferred stock consideration	$ 5,000,000.0
Unrealized gain (loss) on equity investments					$ 336,000